Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

Phase 1 Completed 65 enrolled Chong Kun Dang Pharmaceutical

RandomizedCrossoverOpen-labelTreatment

Summary

This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects

Timeline

Start: 2022-01-14
Primary completion: 2022-03-12
Completion: 2022-04-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CKD-388	Unknown	—	—
Subject	D418	Unknown	—	—

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

Summary

Timeline

Drugs

Indications